Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

The New England Journal of Medicine
S N SinghD Lazzeri

Abstract

Asymptomatic ventricular arrhythmias in patients with congestive heart failure are associated with increased rates of overall mortality and sudden death. Amiodarone is now used widely to prevent ventricular tachycardia and fibrillation. We conducted a trial to determine whether amiodarone can reduce overall mortality in patients with congestive heart failure and asymptomatic ventricular arrhythmias. We used a double-blind, placebo-controlled protocol in which 674 patients with symptoms of congestive heart failure, cardiac enlargement, 10 or more premature ventricular contractions per hour, and a left ventricular ejection fraction of 40 percent or less were randomly assigned to receive amiodarone (336 patients) or placebo (338 patients). The primary end point was overall mortality, and the median follow-up was 45 months (range, 0 to 54). There was no significant difference in overall mortality between the two treatment groups (P = 0.6). The two-year actuarial survival rate was 69.4 percent (95 percent confidence interval, 64.2 to 74.6) for the patients in the amiodarone group and 70.8 percent (95 percent confidence interval, 65.7 to 75.9) for those in the placebo group. At two years, the rate of sudden death was 15 percent in th...Continue Reading

References

Jul 7, 1977·The New England Journal of Medicine·J N Cohn, J A Franciosa
Jul 23, 1992·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial II Investigators
Nov 1, 1992·Journal of the American College of Cardiology·L CeremuzynskiE Lazarczyk-Kedzia
Nov 1, 1990·Circulation·S G Young
Sep 1, 1990·Journal of Molecular and Cellular Cardiology·H E CingolaniR B Stein
Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Dec 1, 1989·Journal of the American College of Cardiology·K Chatterjee
Dec 1, 1989·Journal of the American College of Cardiology·A W HamerJ A Johns
Nov 1, 1988·Circulation·J N Cohn
Oct 1, 1983·American Heart Journal·B N Singh
Feb 1, 1984·British Heart Journal·K von OlshausenW Kübler
Mar 15, 1984·The American Journal of Cardiology·T MeinertzJ Meyer
Jul 1, 1984·The American Journal of Cardiology·D V UnverferthC V Leier
Nov 26, 1993·The American Journal of Cardiology·S N SinghC Colling

❮ Previous
Next ❯

Citations

Apr 13, 1999·Clinical Cardiology·A H Wu, S K Das
Feb 17, 2000·Clinical Cardiology·G V NaccarelliJ C Luck
Jan 1, 1997·Cardiovascular Drugs and Therapy·P Vantrimpont, J L Rouleau
Apr 3, 2007·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Georg Delle KarthGottfried Heinz
Jan 26, 2005·Zeitschrift für Kardiologie·J R Ehrlich, S H Hohnloser
Jul 29, 2005·Zeitschrift für Kardiologie·U C HoppeUNKNOWN Vorstand der Deutschen Gesellschaft fur Kardiologie--Herz- und Kreislaufforschung e.V
Nov 4, 2008·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Lorenz H LehmannMartin Stockburger
Nov 26, 2010·Herzschrittmachertherapie & Elektrophysiologie·C Sohns, M Zabel
Mar 21, 2007·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·Michael E Field, Michael O Sweeney
Aug 10, 2002·Current Cardiology Reports·Gerald V NaccarelliJerry Luck
Jul 23, 2005·Current Heart Failure Reports·Steven Kang, David S Cannom
May 25, 2007·Current Heart Failure Reports·Nazem Akoum, Mohamed H Hamdan
Nov 7, 2001·Current Treatment Options in Cardiovascular Medicine·Carl V. Leier
Nov 1, 2002·Current Treatment Options in Cardiovascular Medicine·B. John HynesGerald V. Naccarelli
Aug 25, 2004·Current Treatment Options in Cardiovascular Medicine·Steven N. SinghJonathan Patrick
Nov 30, 2000·Current Treatment Options in Cardiovascular Medicine·P Ott
Nov 30, 2000·Current Treatment Options in Cardiovascular Medicine·A Auricchio, H Klein
May 28, 2013·Chemico-biological Interactions·Fiona C RothThomas E Massey
Jan 18, 2006·International Journal of Cardiology·Giovanni CioffiCristina Opasich
Mar 31, 2004·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Takuji ToyamaKoichi Taniguchi
Mar 31, 2004·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Albert Flotats, Ignasi Carrió
Oct 9, 2004·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Albert Flotats, Ignasi Carrió
Feb 5, 2008·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Ji ChenErnest V Garcia
Jul 20, 2002·The American Journal of Cardiology·Juan M ArandaJames A Hill
Aug 29, 1996·The American Journal of Cardiology·B N Singh
Sep 18, 1997·The American Journal of Cardiology·D J WilberD E Kopp
Oct 7, 1997·The American Journal of Cardiology·I Singer, S Nisam
Nov 14, 1997·The American Journal of Cardiology·B N Singh
Nov 14, 1997·The American Journal of Cardiology·M D Landers, M J Reiter
Dec 31, 1997·The American Journal of Cardiology·M GheorghiadeR O Bonow

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.